Search

Common inflammatory conditions of the airways, such as chronic rhinitis, nasal polyposis, seasonal and chronic allergic rhinitis can greatly affect a patient's health and quality of life. For each of these disorders, intranasal corticosteroids are suggested as a component of the therapy regimen because they can assist to lessen symptoms by reducing inflammation. In this randomized controlled trial, 30 people with rhinitis were enrolled to evaluate a new nano formulation of fluticasone propionate nano-nasal spray (FP-NNS) with commercially available nasal spray called FP-NS for the treatment of allergic rhinitis (15 to 60 years). 50 mcg dosages of FP-NNS were administered to patients in the morning and evening. This regimen was administered as a nasal spray for a 4-week effectiveness and safety phase. Analysis of variance was used to evaluate each efficacy endpoint. More of our clinical studies have shown that FP-NNS reduces inflammatory indicators in adults and children. [ABSTRACT FROM AUTHOR]

Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects' congestion as determined by the physicians' assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children. [ABSTRACT FROM AUTHOR]